Trastuzumab Completed Phase 2 Trials for Sarcomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00005033Trastuzumab in Treating Patients With Recurrent Osteosarcoma
NCT00104949Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma